Loading data for AURA — first visit, this takes a few seconds.
Aura Biosciences, Inc.
7.00 +0.01 (0.14%)
7.00 +0.00%
- Market Cap
- $725.4M
- Volume
- 831K
- Dividend yield
- n/a
- Next earnings date
- Nov 12, 2026
Aura Biosciences, Inc. (AURA) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $0 | n/a | n/a |
| EPS | -$0.48 | -$0.11 | -2.13% |
Metrics
- Bid
- 5.18
- Market Cap
- 725M
- Revenue (ttm)
- n/a
- Net Income (ttm)
- -131M
- 0.40
- -1.73
- n/a
- -3.45
- P/B (ttm)
- 2.30
- P/S (ttm)
- n/a
- Earnings Date
- Nov 12, 2026
- Ask
- 9.22
- Volume
- 830,853
- Avg. Volume (20D)
- 666,827
- Open
- 7.08
- Previous Close
- 6.99
- Day's Range
- 6.91 - 7.08
- 52-Week Range
- 4.73 - 9.54
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Aura Biosciences, Inc.
View profile →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Industry Biotechnology
Sector Healthcare
IPO Date Oct 29, 2021
Employees 113
Stock Exchange NasdaqGM
Ticker Symbol AURA
Website https://www.aurabiosciences.com